Valneva (VLA) Aktievy
Valneva SE, ett specialiserat vaccinföretag, utvecklar, tillverkar och kommersialiserar profylaktiska vacciner för infektionssjukdomar med ouppfyllda behov. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 6/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 3/6 |
| Utdelningar | 0/6 |
VLA Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Valneva SE Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €2.31 |
| 52 veckors högsta | €5.42 |
| 52 veckors lägsta | €2.14 |
| Beta | 1.4 |
| 1 månads förändring | -7.43% |
| 3 månaders förändring | -49.43% |
| 1 års förändring | -5.38% |
| 3 års förändring | -68.55% |
| 5 års förändring | -78.58% |
| Förändring sedan börsintroduktionen | -78.97% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 13
VLA: Future Travel Vaccines And Lyme Franchise Will Drive Reassessment
Analysts have reduced their price target on Valneva from €10.00 to €7.50, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E multiples as reflected in the latest fair value analysis. What's in the News Valneva revised its 2026 product sales guidance to a range of €135 million to €150 million, with total revenue guidance set at €145 million to €160 million, citing an emerging adverse trend in travel vaccine uptake across key markets driven by geopolitical factors.
Uppdatering av berättelse • May 30
VLA: Weaker Travel Vaccine Demand Will Drive Cautious View On Shares
Analysts have slightly reduced their Valneva price target from €2.15 to €2.10, citing revised assumptions around revenue growth, profit margins and a higher implied future P/E multiple in their updated models. What's in the News Valneva adjusted its 2026 guidance, setting product sales in a range of €135 million to €150 million and total revenue guidance at €145 million to €160 million, citing an emerging adverse trend in travel vaccine uptake across key markets linked to geopolitical factors (Corporate Guidance, Lowered).Analysartikel • May 15
€5.28: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Valneva SE ( EPA:VLA ) just released its latest first-quarter report and things are not looking great. Statutory...Recent updates
Uppdatering av berättelse • Jun 13
VLA: Future Travel Vaccines And Lyme Franchise Will Drive Reassessment
Analysts have reduced their price target on Valneva from €10.00 to €7.50, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E multiples as reflected in the latest fair value analysis. What's in the News Valneva revised its 2026 product sales guidance to a range of €135 million to €150 million, with total revenue guidance set at €145 million to €160 million, citing an emerging adverse trend in travel vaccine uptake across key markets driven by geopolitical factors.Uppdatering av berättelse • May 30
VLA: Weaker Travel Vaccine Demand Will Drive Cautious View On Shares
Analysts have slightly reduced their Valneva price target from €2.15 to €2.10, citing revised assumptions around revenue growth, profit margins and a higher implied future P/E multiple in their updated models. What's in the News Valneva adjusted its 2026 guidance, setting product sales in a range of €135 million to €150 million and total revenue guidance at €145 million to €160 million, citing an emerging adverse trend in travel vaccine uptake across key markets linked to geopolitical factors (Corporate Guidance, Lowered).Analysartikel • May 15
€5.28: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Valneva SE ( EPA:VLA ) just released its latest first-quarter report and things are not looking great. Statutory...Uppdatering av berättelse • May 03
VLA: Lyme Vaccine Progress And Equity Raise Will Shape Balanced Outlook
Analysts have reduced their price target for Valneva from €3.25 to €2.15, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples. What's in the News Valneva filed a follow on equity offering of €37.03 million, covering 15,893,817 ordinary shares at €2.33 per share with attached warrants, under Regulation S (Key Developments).Uppdatering av berättelse • Apr 18
VLA: Lyme Vaccine Progress Will Support Earnings Despite Chikungunya Setback
Analysts have kept their Valneva price target steady at €3.25, citing updated assumptions for discount rate, revenue growth, profit margins and future P/E that broadly support the prior valuation level. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial results for their 6-valent OspA-based Lyme disease vaccine candidate PF-07307405, with efficacy above 70% in reducing confirmed Lyme cases in two pre specified analyses and no safety concerns identified at the time of analysis.Uppdatering av berättelse • Apr 03
VLA: Lyme Vaccine Progress Will Offset Chikungunya Headwinds Over Time
Analysts have raised their Valneva price target from €2.95 to €3.25, citing updated assumptions around revenue growth, profit margins, and a slightly lower future P/E multiple as the main factors behind the change. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial data for their investigational 6 valent OspA based Lyme disease vaccine candidate, with efficacy readings in prespecified analyses and Pfizer planning regulatory submissions after reviewing the results and safety profile (Product related announcement).
Uppdatering av berättelse • Mar 20
VLA: Vaccine Partnerships And Guidance Will Drive Bullish Repricing Potential
Analysts have nudged their price target on Valneva slightly lower to about €6.96 from roughly €6.99, reflecting updated assumptions around discount rates, revenue growth, profit margins and future price-to-earnings levels. What's in the News Elaris FlexCo signed an exclusive global license agreement for Valneva's Clostridioides difficile vaccine candidate VLA84, with plans to use the antigen technology in a next generation program and potential milestone and royalty payments tied to future development, regulatory and commercial outcomes (Key Developments).Uppdatering av berättelse • Mar 06
VLA: Future Travel Vaccine Franchise And Real World Data Will Drive Reassessment
Analysts have reaffirmed their €10.00 price target for Valneva, with updated assumptions showing a slightly higher discount rate and profit margin, alongside a lower future P/E, suggesting a more balanced view of risk and earnings potential. What's in the News Valneva issued earnings guidance for 2026, expecting total revenues of €155 million to €170 million, with product sales of €145 million to €160 million.Uppdatering av berättelse • Feb 20
VLA: Future Lyme Vaccine Milestones Will Shape Bullish Repricing Potential
Analysts have adjusted their fair value estimate for Valneva from €6.51 to about €6.99. This change reflects updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples.Uppdatering av berättelse • Feb 05
VLA: Chikungunya Safety Setbacks Will Weigh On Long Term Earnings Potential
Analysts have reduced their price target on Valneva from €3.25 to €2.95, citing updated assumptions for revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Valneva and Instituto Butantan launched a Pilot Vaccination Strategy in Brazil using single shot chikungunya vaccine IXCHIQ, aiming for 20% to 40% coverage of adults aged 18 to 59 in ten municipalities as part of post marketing effectiveness and safety studies (Key Developments).Uppdatering av berättelse • Jan 22
VLA: Future Vaccine Pipeline Progress Will Support Higher Market Reassessment
Analysts have lifted their fair value estimate for Valneva from €9.50 to €10.00, pointing to adjusted assumptions around discount rates, revenue growth, profit margins and future P/E as the key drivers of the updated price target. What's in the News Valneva decided to voluntarily withdraw the BLA and IND for its chikungunya vaccine IXCHIQ in the US after the FDA suspended the license in August 2025 and later placed the IND on clinical hold following a newly reported foreign serious adverse event that may be plausibly related to vaccination, while causality has not been determined and no active vaccination studies are ongoing (company announcement).Uppdatering av berättelse • Jan 07
VLA: Chikungunya Commercial Uncertainty Will Undermine Long Term Earnings Potential
Analysts have adjusted their price targets for Valneva, with updated assumptions that include a discount rate of 6.76%, revenue growth of 9.16%, a profit margin of 26.93% and a forward P/E of 13.87x, reflecting a recalibration of expectations around the company’s risk profile and earnings outlook. What's in the News Valneva and Serum Institute of India agreed to discontinue their license deal for the single shot chikungunya vaccine, with Valneva regaining full rights to manage supply and commercialization in endemic high risk countries within the funding framework agreed with CEPI and the European Union (Client Announcements).Uppdatering av berättelse • Dec 14
VLA: Higher Long Term Profit Hopes Will Not Offset Rising Risk
Analysts have trimmed their price target for Valneva from €3.75 to €3.25, reflecting higher perceived risk despite more optimistic long term assumptions for revenue growth and profitability. What's in the News Positive Phase 2 antibody persistence and safety data in 304 children for single shot chikungunya vaccine IXCHIQ, supporting full dose selection and planned Phase 3 development in pediatrics (company announcement) Phase 2 Lyme disease vaccine candidate VLA15 shows strong booster response and favorable safety across age groups, reinforcing partnership with Pfizer ahead of planned 2026 BLA and MAA filings, subject to positive Phase 3 results (company announcement) Strategic reorganization to concentrate French operations in Lyon and close the Nantes site.Analysartikel • Oct 01
Subdued Growth No Barrier To Valneva SE (EPA:VLA) With Shares Advancing 29%
Despite an already strong run, Valneva SE ( EPA:VLA ) shares have been powering on, with a gain of 29% in the last...Analysartikel • Sep 10
Is Valneva (EPA:VLA) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Uppdatering av berättelse • Aug 24
Rapid Lyme Vaccine Development And Rising Preventative Healthcare Will Shape Future Markets
Valneva's substantial improvement in net profit margin and sharp reduction in future P/E have led to a notable upward revision in the consensus analyst price target from €6.97 to €7.48. What's in the News Health Canada granted marketing authorization for IXCHIQ, Valneva’s single-dose chikungunya vaccine, for individuals aged 12 years and older, supported by robust antibody persistence and safety data.Analysartikel • Jul 24
Valneva SE's (EPA:VLA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Valneva SE ( EPA:VLA ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month...Ny berättelse • May 14
Upcoming Lyme Vaccine Data Will Unlock Market Opportunities
Potential success of the Lyme disease vaccine could significantly boost future revenue and earnings through strategic regulatory filings and commercialization milestones.Analysartikel • Feb 20
Valneva SE (EPA:VLA) Analysts Just Slashed Next Year's Revenue Estimates By 13%
Market forces rained on the parade of Valneva SE ( EPA:VLA ) shareholders today, when the analysts downgraded their...Analysartikel • Feb 06
Valneva SE (EPA:VLA) Stock Catapults 35% Though Its Price And Business Still Lag The Industry
Valneva SE ( EPA:VLA ) shares have had a really impressive month, gaining 35% after a shaky period beforehand. Not all...Analysartikel • Nov 22
Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Valneva SE ( EPA:VLA ) share price has dived 25% in the last thirty days...Analysartikel • Nov 10
€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Valneva SE ( EPA:VLA ) just released its latest quarterly results and things are looking bullish. Results overall were...Analysartikel • Sep 19
Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive
Valneva SE ( EPA:VLA ) shares have had a horrible month, losing 29% after a relatively good period beforehand. For any...Aktieägarnas avkastning
| VLA | FR Biotechs | FR Marknad | |
|---|---|---|---|
| 7D | 0.8% | -1.6% | 0.07% |
| 1Y | -5.4% | 260.3% | 7.3% |
Avkastning vs industri: VLA presterade sämre än French Biotechs branschen som gav 260.3 % under det senaste året.
Avkastning vs Marknaden: VLA presterade sämre än French marknaden som gav 7.3 % under det senaste året.
Prisvolatilitet
| VLA volatility | |
|---|---|
| VLA Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FR Market | 11.1% |
| 10% least volatile stocks in FR Market | 2.7% |
Stabil aktiekurs: VLA s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för French.
Volatilitet över tid: VLA s veckovolatilitet ( 13% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av French aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1998 | 674 | Thomas Lingelbach | valneva.com |
Valneva SE, ett specialiserat vaccinföretag, utvecklar, tillverkar och marknadsför profylaktiska vacciner mot infektionssjukdomar med ouppfyllda behov. Företaget erbjuder IXIARO, ett inaktiverat japanskt encefalitvaccin härlett från Vero-cellkultur, avsett för aktiv immunisering mot japansk encefalit; DUKORAL, ett oralt vaccin för förebyggande av diarré orsakad av Vibrio cholera eller värmelabila toxinproducerande enterotoxigena Escherichia coli-bakterier; och IXCHIQ/VLA1553, ett levande försvagat engångsvaccin för förebyggande av sjukdom orsakad av chikungunyavirus. Bolaget utvecklar också VLA15, en vaccinkandidat mot Borrelia, den bakterie som orsakar borrelia; S4V2, en tetravalent biokonjugatvaccinkandidat mot shigellos, en diarréinfektion som orsakas av Shigellabakterier; VLA1601, en vaccinkandidat mot zikaviruset, en myggburen virussjukdom; VLA1554, en vaccinkandidat mot humant metapneumovirus, VLA84, en vaccinkandidat för förebyggande av primär symptomatisk clostridium difficile-infektion, och VLA2112, en vaccinkandidat för behandling av patienter med epstein-barr-virus.
Valneva SE Sammanfattning av grunderna
| VLA grundläggande statistik | |
|---|---|
| Börsvärde | €434.10m |
| Vinst(TTM) | -€138.03m |
| Intäkter(TTM) | €156.33m |
2.8x
P/S-förhållande-3.2x
P/E-förhållandeÄr VLA övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| VLA resultaträkning (TTM) | |
|---|---|
| Intäkter | €156.33m |
| Kostnad för intäkter | €195.84m |
| Bruttovinst | -€39.51m |
| Övriga kostnader | €98.52m |
| Intäkter | -€138.03m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
Aug 13, 2026
| Vinst per aktie (EPS) | -0.73 |
| Bruttomarginal | -25.27% |
| Nettovinstmarginal | -88.30% |
| Skuld/egenkapitalförhållande | 237.7% |
Hur har VLA utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/19 10:13 |
| Aktiekurs vid dagens slut | 2026/06/19 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Valneva SE bevakas av 15 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Vladimira Urbankova | Erste Group Bank AG |
| Simon Scholes | First Berlin Equity Research GmbH |
| Rajan Sharma | Goldman Sachs |